Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors while in the central nervous method, conolidine modulates alternate molecular targets. A Science Developments study found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://johnl940cjs4.bloggactif.com/profile